Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Patrick M. O’Neil(Medical University of South Carolina), Andreas L. Birkenfeld(University Hospital Carl Gustav Carus), Barbara McGowan(Guy's and St Thomas' NHS Foundation Trust), Ofri Mosenzon, Sue D. Pedersen(LMC Diabetes & Endocrinology (Canada)), Sean Wharton(York University), Charlotte Giwercman Carson(Novo Nordisk (Denmark)), Cecilie H. Jepsen(Novo Nordisk (Denmark)), Maria Kabisch(Novo Nordisk (Denmark)), John Wilding(University of Liverpool)
The Lancet
August 1, 2018
Cited by 793

Abstract


Related Papers

No related papers found

Powered by citation graph analysis